Beam Therapeutics Q2 2024 GAAP EPS $(1.11) Beats $(1.25) Estimate, Sales $11.772M Miss $14.183M Estimate
Portfolio Pulse from Benzinga Newsdesk
Beam Therapeutics (NASDAQ:BEAM) reported Q2 2024 GAAP EPS of $(1.11), beating the estimate of $(1.25) but showing a year-over-year decrease. Sales were $11.772M, missing the $14.183M estimate and showing a significant decline from the previous year.
August 06, 2024 | 10:39 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Beam Therapeutics reported Q2 2024 GAAP EPS of $(1.11), beating the estimate of $(1.25) but showing a year-over-year decrease. Sales were $11.772M, missing the $14.183M estimate and showing a significant decline from the previous year.
While Beam Therapeutics beat EPS estimates, the significant miss on sales and the year-over-year decline in both EPS and sales could create mixed reactions in the market. The EPS beat might provide some support, but the sales miss and decline could weigh on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100